Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Berlin - Delayed Quote EUR

UroGen Pharma Ltd. R (UR8.BE)

10.20
0.00
(0.00%)
At close: May 2 at 9:40:04 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
90,398
90,398
82,713
64,357
48,042
Cost of Revenue
8,881
8,881
9,361
7,654
5,157
Gross Profit
81,517
81,517
73,352
56,703
42,885
Operating Expense
178,299
178,299
138,888
135,744
135,177
Operating Income
-96,782
-96,782
-65,536
-79,041
-92,292
Net Non Operating Interest Income Expense
-3,620
-3,620
-12,074
-7,500
212
Other Income Expense
-23,640
-23,640
-20,714
-21,487
-17,291
Pretax Income
-124,042
-124,042
-98,324
-108,028
-109,371
Tax Provision
2,832
2,832
3,920
1,755
1,449
Net Income Common Stockholders
-126,874
-126,874
-102,244
-109,783
-110,820
Diluted NI Available to Com Stockholders
-126,874
-126,874
-102,244
-109,783
-110,820
Basic EPS
-3.02
-2.96
-3.55
-4.79
-4.96
Diluted EPS
-3.02
-2.96
-3.55
-4.79
-4.96
Basic Average Shares
37,413.38
42,876.74
28,834.30
22,806.81
22,347.48
Diluted Average Shares
37,413.38
42,876.74
28,834.30
22,806.81
22,347.48
Total Operating Income as Reported
-96,782
-96,782
-65,536
-79,041
-92,292
Total Expenses
187,180
187,180
148,249
143,398
140,334
Net Income from Continuing & Discontinued Operation
-126,874
-126,874
-102,244
-109,783
-110,820
Normalized Income
-108,379.31
-108,379.31
-85,217.92
-92,751.39
-98,197.57
Interest Income
8,901
8,901
2,641
938
365
Interest Expense
12,521
12,521
14,715
8,438
--
Net Interest Income
-3,620
-3,620
-12,074
-7,500
212
EBIT
-111,521
-111,521
-83,609
-99,590
-109,371
EBITDA
-110,335
-110,335
-81,904
-97,773
-107,598
Reconciled Cost of Revenue
8,881
8,881
9,361
7,654
5,157
Reconciled Depreciation
1,186
1,186
1,705
1,817
1,773
Net Income from Continuing Operation Net Minority Interest
-126,874
-126,874
-102,244
-109,783
-110,820
Total Unusual Items Excluding Goodwill
-23,411
-23,411
-21,552
-21,559
-17,291
Total Unusual Items
-23,411
-23,411
-21,552
-21,559
-17,291
Normalized EBITDA
-86,924
-86,924
-60,352
-76,214
-90,307
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-4,916.31
-4,916.31
-4,525.92
-4,527.39
-4,668.57
12/31/2021 - 2/20/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GON.F Geron Corporation
1.2200
+1.67%
 
I9SA.F Verona Pharma plc
62.20
-1.58%
 
ZH6.BE Biohaven Ltd. R
20.20
+2.54%
 
49BA.BE BeiGene Ltd
222.00
-4.31%
 
NUVB Nuvation Bio Inc.
2.4600
+8.37%
 
ALLO Allogene Therapeutics, Inc.
1.7000
+0.59%
 
SLS SELLAS Life Sciences Group, Inc.
1.7400
+7.41%
 
BHVN Biohaven Ltd.
22.85
+1.78%
 
VRNA Verona Pharma plc
72.73
+0.65%
 
ABEO Abeona Therapeutics Inc.
6.56
-4.51%